Xenoport shares get a lift from positive drug trial results

xenoport-logoXenoport, the Santa Clara biopharmaceutical, reported positive preliminary results today from a Phase 2 clinical trial of its treatment for patients with spasticity related to spinal cord injury. Patients given twice-daily doses showed “statistically significant improvement” compared to those receiving a placebo.

The company also said the drug candidate, arbaclofen placarbil, was well tolerated, with none of the 37 patients in the study withdrawing because of adverse effects. Side effects reported in small fractions of the patients included urinary tract infection, pain in the extremities, insomnia and sore throat.

Xenoport shares rose $1.51, or 7 percent, to $23.17. They are down six percent so far in 2009 and remain well below the 52-week high of $51.42 they touched on Aug. 15.

Shares of Xenoport touched a 52-week low of $13.36 in April after Xenoport and its partner, GlaxoSmithKline, reported that a clinical trial of its treatment for neuropathic pain associated with diabetic peripheral neuropathy in adults “did not demonstrate a statistically significant improvement” when compared to a placebo.

 

Tags: , ,

 

Share this Post



 
 
 
 
 
css.php